Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 9 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.Not yet recruitingNCT07083375Phase 2
• Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal AdenocarcinomaRecruitingNCT07082439Phase 2
• Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingNCT07080216Phase 1/2
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerRecruitingNCT07079631Phase 1/2
• Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07079410Phase 2
• Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
• Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver ResectionNot yet recruitingNCT07077798Not applicable
• Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
• WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical TherapyNot yet recruitingNCT07077369Phase 1
• Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant TumorsRecruitingNCT07073534Phase 1/2
• Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]RecruitingNCT07071961Phase 2
• Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
• Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2
• Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Phase 2
• Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEARecruitingNCT07070466Phase 2
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Phase 1/2
• A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNot yet recruitingNCT07069270Phase 2
• Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal CancerRecruitingNCT07068763Phase 2
• Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ CancerNot yet recruitingNCT07068516Phase 3
• Adjuvant Immunotherapy for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07067450Not applicable
• Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck CancerRecruitingNCT07065630Phase 2
• Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung CancerNot yet recruitingNCT07064876Phase 2
• A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Not applicable
• A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTCNot yet recruitingNCT07062328Phase 2
• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruitingNCT07061964Phase 2
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingNCT07061535Phase 2
• Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerNot yet recruitingNCT07059949Phase 2
• Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver TransplantRecruitingNCT07059494Phase 4
• A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaRecruitingNCT07059299Phase 1
• A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma CancerRecruitingNCT07059221Phase 1/2
• A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)RecruitingNCT07058012Phase 2
• Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerRecruitingNCT07057791Phase 2
• Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT07055841Phase 2
• A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2
• MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell CarcinomaRecruitingNCT07054307Phase 1
• A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System TumorsNot yet recruitingNCT07053150Phase 2
• Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT CarcinomaRecruitingNCT07050186Phase 2
• Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLCRecruitingNCT07050056Phase 2
• Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCRecruitingNCT07050043Phase 3
• SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue SarcomaRecruitingNCT07049848Phase 2
• QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07049185Phase 2
• Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07047586Phase 2
• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07043400Phase 3
• A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian CancerRecruitingNCT07042802Phase 1/2
• Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCCNot yet recruitingNCT07041788Phase 2
• Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCRecruitingNCT07040072Phase 1
• Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant TherapyRecruitingNCT07039656Phase 2
• Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07039162Phase 2
• Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCRecruitingNCT07038629Phase 2
• A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNot yet recruitingNCT07038460Phase 2
• ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT07038096Phase 1/2
• Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07035392Phase 2
• Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical StudyNot yet recruitingNCT07034118Phase 1
• A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FLNot yet recruitingNCT07031700Phase 2
• A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07031154Phase 2
• Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingNCT07030140Phase 2
• Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingNCT07027124Phase 2
• Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal CancerNot yet recruitingNCT07025850Phase 1/2
• QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal CancerNot yet recruitingNCT07025239Phase 3
• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Phase 3
• SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid TumorsRecruitingNCT07022002Phase 2
• ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT07021989Phase 2
• AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal CancerNot yet recruitingNCT07021950Phase 2
• Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous CarcinomaNot yet recruitingNCT07019181Phase 2
• An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction AdenocarcinomaRecruitingNCT07018570Phase 2
• Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Phase 2
• GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerRecruitingNCT07017829Phase 2
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerRecruitingNCT07017673Phase 2
• ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNot yet recruitingNCT07015853Phase 2
• Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial CancerNot yet recruitingNCT07013851Phase 2
• Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2
• FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Phase 3
• Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.Not yet recruitingNCT07009925Phase 2
• QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRCNot yet recruitingNCT07009145Phase 2
• Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）Not yet recruitingNCT07007767Phase 2
• Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingNCT07007728Phase 2
• Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaRecruitingNCT07007273Phase 2
• Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
• Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNot yet recruitingNCT07004335Phase 4
• Application of KRAS Vaccine in the Treatment of KRAS-mutated MalignanciesRecruitingNCT07004244Phase 1
• Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingNCT07003815Phase 2
• INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell CarcinomaRecruitingNCT07002346Phase 3
• Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerRecruitingNCT07001618Phase 2
• Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)RecruitingNCT06999980Phase 2
• Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999707Phase 2
• Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999694Phase 2
• Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer PatientsNot yet recruitingNCT06999252Phase 2
• JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingNCT06998771Phase 2
• Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLCNot yet recruitingNCT06998719Phase 2
• A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical CancerRecruitingNCT06998394Phase 2
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract MalignanciesNot yet recruitingNCT06993025Phase 2
• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 3
• TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical TrialNot yet recruitingNCT06987123Phase 2
• Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical CancerNot yet recruitingNCT06986057Phase 2
• A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
• Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingNCT06984146Phase 2
• A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerNot yet recruitingNCT06981858Phase 2

← Immune Checkpoint Inhibitors overview